Silexion Therapeutics Corp
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
. Other Information.
(a)Unreported Information. The Company does not have any information required to be disclosed in a Current Report on Form 8-K during the fourth quarter of the year ended December 31, 2024 that has not yet been reported.
(b)Insider trading arrangements. During the three-month period ended December 31, 2024, none of our directors or officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K promulgated by the SEC.
Item 9C
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.